Results: Urinary kallikrein activity varied substantially (F ‫؍‬ 5.30, P ‫؍‬ 0.006) across the three ethnic groups, with African-American values ෂ50% lower than Caucasian (P ‫؍‬ 0.005) or Asian (P ‫؍‬ 0.02). Ethnicity and gender (T ‫؍‬ 3.24, P ‫؍‬ 0.001) had independent effects on kallikrein, with women excreting ෂ50% more kallikrein than men, regardless of ethnicity. Subjects at genetic risk of hypertension were over-represented (P ‫؍‬ 0.048)
Introduction
Essential hypertension is a multifactorial disease influenced by a combination of genetic and environmental factors. 1 Investigations have shown that more than one gene is responsible for essential hypertension, though the specific genes remain elusive. 2 'Intermediate phenotypes' 1 are traits associated with essential hypertension with such advantageous properties as earlier penetrance, superior heritability, or logicial involvement in the pathogenesis of the disease; such phenotypes may be valuable in profiling at-risk individuals for future development of the ultimate disease trait.
Urinary kallikrein excretion has been proposed as such an 'intermediate phenotype'. 1 The hypotensive property of human urine, now known as kallikrein, has been described since 1909. 3 However, the relationships between urinary kallikrein and hypertension have only more recently been elucidated, over the last 30 years. Urinary kallikrein enzymatically converts low molecular weight kininogen to lys-bradykinin (kallidin), which pharmacologically exhibits both renal vasodilator and natriuretic properties; if these properties occur in vivo, the potential of the system for decreasing blood pressure is clear. 3 Urinary kallikrein excretion displays highly familial aggregation: up to ෂ51% of its phenotypic variance is attributable to a single genetic locus, with a dominant allele for high total urinary
Journal of Human Hypertension kallikrein excretion demonstrated in Utah kindreds. 4 Recently, Song et al 5 discovered several DNA polymorphisms in the 5Ј flanking region of the renal kallikrein gene, which is localized to human chromosome 19q13.3-q13. 4 ; 5 10 different promoter alleles showed variable transcriptional activity in vitro, and the promoter allele frequencies differed by ethnicity among Caucasian, African-American, and Asian subjects. Several studies have demonstrated ethnic differences in urinary kallikrein excretion, with African-Americans consistently having lower urinary kallikrein excretion when compared to Caucasians, across both normal and high blood pressure strata. 2, [6] [7] [8] [9] In addition to ethnic differences in urinary kallikrein excretion, Albano et al 10 and Kailasam et al 11 have described a gender difference, with higher urinary kallikrein excretion in premenopausal women than in men. Although many investigations have described ethnic differences in essential hypertension, most such studies have compared African-Americans and Caucasians. Very few ethnic studies in hypertension have directly compared Asians to other groups. Asians represent the most populous ethnic group in the world, 12 and hypertension prevalence and consequent mortality have increased in China and Taiwan in recent years, 13, 14 with the morbid sequelae of hypertension accounting for up to 25-50% of all deaths in China each year. 15 Thus, it is becoming imperative to better understand factors contributing to hypertension in Asians. In our investigation, we studied normotensive young adults to detect whether differences in urinary kallikrein excretion occurred in subjects stratified by ethnicity as well as genetic risk of hypertension.
Subjects and methods

Subjects
All subjects gave written informed consent, and the study was approved by the Human Subjects Committee at the University of California, San Diego. A total of 204 normotensive subjects (109 men, 95 women) were studied, all of whom lived in southern California. The age range was 20-53 years, with a mean age of 31 ± 0.6 years. The subjects were stratified by ethnicity based on self-identification, as well as the self-identification of all four grandparents: 119 Caucasian (ancestry in Europe or the Middle East; 61 males, 58 females), 33 African-Americans (ancestry in sub-Saharan Africa); 22 males, 11 females, and 52 Asians (ancestry in east Asia (China, Korea, Vietnam, or the Philippines); 26 males, 26 females). All subjects were normotensive (blood pressure Ͻ 140/ Ͻ 90 mm Hg) with no prior history of hypertension, and none were consuming medications which influence blood pressure. Family history of essential hypertension in first degree relatives (parents or siblings, before the age of 60 years) was obtained as previously described; 16 only subjects of unambiguous family history (positive or negative) were included in this study. All women were premenopausal adults, but were not studied at a particular phase of the menstrual cycle.
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Study design
Each subject completed a written questionnaire from which information regarding ethnicity, family history of hypertension, 16 and past medical history was obtained. Height and body weight were measured, and the blood pressure was taken with the subject in the seated position, using a Dinamap automatic oscillometric sphygmomanometer (Critikon Inc, Tampa, FL, USA), to preclude observer bias. Timed (4 h) and spot (untimed) urine samples were obtained and frozen at −70°C before assay.
Assays
Urine samples were assayed for kallikrein (alkaline amidolytic) activity using the chromogenic substrate S-2266 ([D]Val-Leu-Arg-paranitroanilide; Kabi Pharmacia, Franklin, OH, USA) as previously described. 11, 17 The activity of kallikrein per litre of urine (units/litre, U/L) is calculated from the formula: U/L = (9.55)(A), where A = absorbance, after a 30 min assay incubation, of the paranitroanilide product in a spectrophotometer at 405 nm.
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Kallikrein activity was linear with A 405 (up to A 405 = 0.18), with time of incubation (up to 120 min) and amount of urine assayed (up to 400 l); a typical assay included 200 l of urine as enzyme source. Repeated freezing and thawing (up to 4 cycles) did not affect enzymatic activity. Inclusion or exclusion of the kallikrein inhibitor aprotinin (Trasylol, Miles Inc., West Haven, CT, USA) indicated that ෂ25% of human urinary S-2266 amidolytic activity in the absence of aprotinin was non-kallikrein (likely urokinase) 17 ; thus, aprotinin (20 kallikrein inhibitory units/ml) was routinely included in the assay blank, to assure specificity for kallikrein measurement. The inter-assay coefficient of variation was 18.1%, and activities from n = 20 samples measured on two separate occasions correlated highly (Spearman R = 0.92, P Ͻ 0.01). In n = 87 subjects, activity correlated highly (Spearman R = 0.82, P Ͻ 0.0001) when results were compared for kallikrein excretion normalised to time (units/4 h) vs creatinine excretion (units/gram creatinine).
Clinical chemistries (serum or urine, electrolytes or creatinine) were measured by spectrophotometric autoanalyzer. Plasma renin activity was determined by radioimmunoassay of angiotensin I formed from endogenous renin substrate (Incstar Corporation, Stillwater, MN, USA). Urine aldosterone concentration was determined by radioimmunoassay (Biotecx Laboratories, Houston, TX, USA).
Statistics
Results are expressed as the mean ± one s.e.m. for continuous variables, or as proportions for dichotomous variables. Results were analysed by one-way ANOVA for ethnicity, and post hoc analyses were performed using the Bonferroni correction. For comparisons of two groups, unpaired t-tests were performed. Two-tailed tests were generally performed, unless a prior directional hypothesis was stated. For small samples or data not distributed normally, group means were compared by the Mann-Whitney U test. Proportions were evaluated by Fisher's exact test or chi-square test. Non-parametric correlations were performed by the Spearman rank correlation method. Multiple regression analysis was done to simultaneously test the effects of several independent variables on kallikrein excretion; for stepwise regression, the criterion for entry of an independent variable into the final model was alpha Ͻ0.05. Frequency distributions were tested for number of components in the distribution by maximum likelihood analysis, using the program ADMIX for DOS operating systems. 16 Power analyses for continuous variables were done to assess sample size required to detect a statistically significant difference between two groups. Statistical analyses were performed on SPSS version 8.0 for Windows (SPSS (Statistical Package for the Social Sciences), Chicago, IL, USA) on an IBM compatible microcomputer, or on InStat version 2.03 (GraphPad Software, San Diego, CA, USA) on a Macintosh computer. (Table 1) The three normotensive ethnic groups were comparable in blood pressures (all F Ͻ 0.5, P Ͼ 0.6), and gender (P = 0.247), though the groups differed somewhat in age (F = 11.3, P Ͻ 0.001; Asians younger (P Ͻ 0.001)), body mass index (F = 8.9, P Ͻ 0.001; African-Americans greater (P = 0.014 to P Ͻ 0.001), and proportion of positive hypertension family his- Journal of Human Hypertension tories (chi square = 20.9, P Ͻ 0.001; African-Americans more often positive).
Results
Subject characteristics
Urinary biochemistries: effects of ethnicity on kallikrein
The three ethnic groups differed substantially in kallikrein excretion (F = 5.3, P = 0.006), with AfricanAmericans excreting approximately half the activity found in the other two groups (P = 0.005 to P = 0.02). The Caucasian and Asian groups had comparable kallikrein excretion (P = 1.0). Although sodium excretion was comparable among the three groups (P = 0.547), a significant differences in urinary potassium excretion was observed between the three ethnicities (F = 11.7, P Ͻ 0.001), with Caucasians excreting higher amounts of potassium when compared to African-Americans (P Ͻ 0.001) or Asians (P = 0.002). There were also significant differences in the urinary Na + /K + ratio (F = 4.9, P = 0.008), especially between Caucasians and Asians (P = 0.011).
When both ethnicity and potassium excretion were considered simultaneously as determinants of kallikrein by ANCOVA (analysis of covariance), both ethnicity (F = 3.25, P = 0.041) and potassium excretion (F = 18.99, P Ͻ 0.001) were significant predictors of kallikrein excretion.
Effects of gender on kallikrein
In this sample, women (n = 95) excreted ෂ50% more kallikrein than men (n = 109) (702 ± 51.5 vs 468 ± 50.4 mU/gm creatinine; T = 3.24, P = 0.001). When both gender and potassium excretion were considered simultaneously as determinants of kallikrein by ANCOVA (analysis of covariance), both gender (F = 4.26, P = 0.040) and potassium excretion (F = 16.8, P Ͻ 0.001) were significant predictors of kallikrein excretion.
A two-way ANOVA (Figure 1 ) was performed to analyse the interaction of ethnicity and gender on urinary kallikrein activity (Table 1 ). There were significant differences in urinary kallikrein activity among the three ethnic groups (F = 3.65, P = 0.028) as well as between the two genders (F = 6.99, P = 0.009), with females excreting more kallikrein. However, there was no interaction of the ethnicity and gender effects on urinary kallikrein activity (P = 0.921); that is, females excreted more kallikrein than males, regardless of ethnicity.
Family history of hypertension
The hypertension family history groups did not differ in mean kallikrein excretion in this sample (T = −0.42, P = 0.68): 562 ± 57 mU/gm creatinine in family history positives (n = 101) vs 592 ± 47 units/gram creatinine in family history negatives (n = 103). However, by the Kolmogorov-Smirnov test, the distribution of kallikrein excretion (mU/gm creatinine) in this sample was not normal (Z = 2.15, n = 204, P = 0.0002). Kallikrein data were then log[10]-transformed in an attempt to normalise the distribution by compressing outliers; even then, the frequency distribution still deviated from the normal (Kolmogorov-Smirnov Z = 1.46, n = 204, P = 0.289). groups revealed an over-representation of the family history positive group in the lower mode. Over-representation of the family history positive group in the lowest log[10]-kallikrein strata was confirmed by chi square analysis: in 15 individuals with the lowest kallikrein excretions (at 43.1 ± 7.2 mU/gm creatinine), there were 11 family history positives and 4 family history negatives, while in the remaining 189 individuals with higher kallikrein excretions (at 620 ± 38.1 mU/gm creatinine), there were 90 family history positives and 99 family history negatives (Fisher's exact test, P = 0.048).
Multiple determinants of kallikrein excretion: gender and potassium
To control for the effects of several independent variables on kallikrein excretion (as the dependent variable), we conducted stepwise multiple linear regression analysis (Table 2) , simultaneously evaluating nine putative determinants (ethnicity, gender, The nine independent variables initially considered in this model were (see Table 1 for definitions and units of measurement): ethnicity, gender, age, body mass index, systolic blood pressure, family history for hypertension, urinary potassium excretion, urinary sodium excretion, and urinary sodium/potassium ratio. Results of the final model, after stepwise multiple linear regression (criterion for entry: alpha Ͻ0.05), are shown. In this global regression model, F = 14.1, multiple R = 0.350, adjusted R 2 = 0.114, n = 204, P Ͻ 0.0001. Abbreviations as in Table 1 . Numbers in bold: statistically significant (Pр0.05).
age, body mass index, systolic blood pressure, family history for hypertension, urinary potassium excretion, urinary sodium excretion, and urinary sodium/potassium ratio). This stepwise model retained variables with alpha Ͻ 0.05.
In this analysis (Table 2) , gender (T = 2.06, P = 0.040), and urinary excretion of potassium (T = 4.10, P = 0.0001) remained significant predictors of urinary kallikrein activity, in a model which predicted ෂ11.4% of the phenotypic variance in kallikrein (F = 14.1, multiple R = 0.350, adjusted R 2 = 0.114, n = 204, P Ͻ 0.0001).
Potassium as a determinant of kallikrein
Since potassium excretion predicted kallikrein excretion (Table 2) , we tested the effect of potassium in vitro on urinary kallikrein activity in the enzymatic assay; addition of 50 mEq/L KCl (an amount exceeding the ethnicity variations in K + excretion; Table 1 ) to urine samples prior to assay did not measurably alter kallikrein activity in samples with either high (0.678 units/liter) or low (0.275 units/liter) activity.
To explore further the role of potassium as a determinant of kallikrein excretion in this sample, we evaluated urinary kallikrein as a univariate function of urinary potassium excretion ( Figure 3) ; the two were significantly correlated (R = 0.323, n = 204, P Ͻ 0.0001). Since the ethnic groups were not matched for potassium excretion (Table 1) , we evaluated the dependence of kallikrein on potassium separately for each group (Figure 3) . In each ethnic group, the kallikrein/potassium slope was posi- In a subset of 19 subjects (10 white, 9 black), we also measured the urinary excretion of aldosterone (Table 3) . In this subset, black individuals showed diminished excretion of not only kallikrein activity (by 83%, P = 0.022) and potassium (by 38%, P = 0.045), but also aldosterone (by 55%, P = 0.0003).
Discussion
Ethnicity
The excretion of renal kallikrein, the hypotensive property in human urine, 3 is diminished in established human essential hypertension. 3 Because kallikrein excretion may also mark the risk of development of hypertension and because the prevalence of hypertension varies widely across ethnic strata, 1, [12] [13] [14] [15] 18 we sought to understand how ethnicity, 11 environment, 19 gender, 10, 11 and genetic risk of hypertension 4 interact to influence renal kallikrein excretion. In particular, we studied three ethnic groups from widely differing geographic sites of ancestry (Europe, sub-Saharan Africa, and east Asia), since previous reports on kallikrein excretion have not directly compared more than two such groups. 1, 8, 9, 11, 20 Reports over the past two decades have demonstrated substantial ethnic differences in renal kallikrein excretion, 2,6-9 with African-Americans displaying consistently lower kallikrein activity than Caucasians. Here we found a substantial diminution in urinary kallikrein excretion in African-Americans (Table 1 ; F = 5.3, P = 0.006), but no difference (P = 1.0) between Caucasian and Asian values. Because potassium also influences kallikrein excretion, 19 we simultaneously evaluated the effects of ethnicity and potassium excretion on kallikrein by ANCOVA, finding significant independent determination by both ethnicity (F = 3.25, P = 0.041) and potassium (F = 18.99, P Ͻ 0.001).
Gender
Gender has a substantial influence on human kallikrein excretion, with females excreting consistently higher activities than males when so stratified. 10, 11 The gender difference in kallikrein excretion has been attributed to an effect of the female menstrual cycle, wherein kallikrein rises ෂ50% from the mid-follicular to the mid-luteal phase of the cycle. 10, 11 Black women notably lack the cycle effect on kallikrein.
11 Although our female subjects were not studied at a particular phase during the menstrual cycle, we still observed ෂ50% higher kallikrein excretion (T = 3.24, P Ͻ 0.001) in females (702 ± 51.5 mU/gm creatinine, n = 95) than males (468 ± 50.4 mU/gm creatinine, n = 109), and the gender effect was independent of ethnicity ( Figure 1 ). Hence, a cycle effect on kallikrein cannot completely explain the gender difference (Figure 1) , since black females do not have a cycle effect on kallikrein. Each subject was normotensive, and a member of the original dataset (Table 1) . Mann-Whitney U test. Abbreviations as in Table 1 . Numbers in bold: statistically significant (P р 0.05).
may vary in its prevalence, natural history, consequences, and responses to treatment. 21 Our results indicate that excretion of kallikrein, the level of which may mark individuals for genetic risk of hypertension 4 and salt sensitivity of blood pressure, 22, 23 is substantially different in women, perhaps contributing to the gender difference in the agedependent onset of hypertension.
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Heredity: family history of hypertension
Gender and race are both determined by heredity. We also explored the role of genetic risk for development of hypertension in these still-normotensive 204 individuals, as indexed by family history of hypertension in a first-degree relative. 16, 24 We have previously shown hypertension family history to influence such potentially pathogenic traits as baroreceptor slope 24 or the cardiac response to alpha 2 -adrenergic blockade. 16 Such early phenotypic responses, occurring in at-risk subjects even before the onset of hypertension, may qualify as more informative 'intermediate phenotypes' 1, 2, 16 in the genetic analysis of this complex trait.
In this sample, heterogeneity of kallikrein distributions (Figure 2 (histogram) ) corresponded to hypertension family history (chi-square = 29.6, P Ͻ 0.001), with the lower kallikrein strata enriched in family history positives (P = 0.048). Berry et al 4 also found, by maximum likelihood analysis, that the frequency distribution of human urinary kallikrein excretion was bimodal. Nonetheless, we did not find family history to be a strong univariate predictor for urinary kallikrein activity in this sample of normotensive individuals (T = −0.42, P = 0.68). In a trait which is not normally distributed, the assumptions underlying parametric statistical tests (such as ttests and ANOVAs) may be violated, leading to false negative conclusions. 16, 25 Other investigations have found variable effects of family history on kallikrein excretion in normotensive individuals, with some studies finding no relationship. 26, 27 However, other studies, especially in children, have shown decreased urinary kallikrein activity in normotensive individuals with positive family history of essential hypertension. 9, [28] [29] [30] Our subject age range was 20-53 years, with a mean age of 31 ± 0.6 years; sampling only normotensive adults up to the age of 53 years may create a selection bias, in that many hypertension family history positive individuals have already become hypertensive by the third or fourth decades of life. Thus, studies in substantially younger individuals stratified by family history of hypertension 9, [28] [29] [30] may be more likely to detect trait differences linked to genetic risk of hypertension.
Potassium: role and mechanism
Potassium intake exerts a well-documented effect on kallikrein excretion in humans. 8, 19, 31 Dietary potassium is largely handled by gastrointestinal absorption and subsequent renal excretion, 32, 33 so that variations in urinary potassium excretion represent variations in dietary potassium intake.
We found that potassium excretion was a major predictor of kallikrein excretion, and a major covariate for the effects of both gender and race on kallikrein excretion. Indeed, African-Americans, who displayed the lowest kallikrein excretions among the three ethnic groups studied (Table 1, Figure 1 ) differed from Caucasians in not only diminished kallikrein excretion, but also diminished potassium excretion (Table 1) . Among nine independent demographic and biochemical variables, potassium excretion was the most important predictor of kallikrein excretion in this sample (Table 2 ; F = 4.10, P = 0.0001).
However, potassium is unlikely to be the sole determinant of kallikrein excretion. First of all, even in the multivariate analysis (Table 2) , not only potassium excretion (T = 4.10, P = 0.0001) but also gender (T = 2.06, P = 0.040) predicted kallikrein excretion. Second, ANCOVA analyses revealed independent effects for gender (F = 4.26, P = 0.040) and potassium excretion (F = 16.8, P Ͻ 0.001) on kallikrein excretion; and for race (F = 3.25, P = 0.041) and potassium excretion (F = 18.99, P Ͻ 0.001) on kallikrein excretion. Third, although African-Americans excreted less potassium than Caucasians (Table 1 ; P Ͻ 0.001), their potassium excretion was comparable to that in Asians (Table 1 ; P = 0.863), while kallikrein excretion was still diminished (Table 1 ; P = 0.020); thus, an independent effect of ethnicity on kallikrein excretion is apparent. Finally, previous carefully controlled studies, with fixed and comparable dietary exposures, have clearly documented ethnicity as a determinant of kallikrein excretion, especially in studies comparing African-Americans and Caucasians. 11, 20 How (mechanistically) might potassium have influenced the ethnic variations in kallikrein excretion in our sample? One likely mediator is aldosterone, since potassium directly stimulates aldosterone biosynthesis and release from the adrenal cortex zona glomerulosa 8, 34 and kallikrein is an aldosterone responsive target in man. 8, [35] [36] [37] Indeed, we documented substantial diminutions in the renal excretion of not only kallikrein and potassium, but also aldosterone (by 55%, P = 0.0003) when comparing a subset of African-Americans to Caucasians within this sample (Table 3) .
What are the consequences or implications of the observed ethnic variations in potassium and kallikrein excretion? Prior studies have shown that African-Americans, a group at relatively high risk for development of hypertension, 1, 6, 18 have lower potassium excretion than Caucasians, 18, 32 an alteration likely secondary to ethnic differences in potassium intake, since urinary potassium excretion correlates with dietary potassium. 32, 33 Urinary potassium excretion varies directly with urinary kallikrein excretion, 9, 19 and spontaneous variation in urinary potassium excretion may explain up to ෂ23% of the variance in kallikrein excretion within monozygotic twin pairs. 19 Dietary potassium supplementation not only decreases blood pressure 32, 38, 39 but also increases kallikrein excretion. 32, 38, 39 Our results therefore raise once again the possibility that dietary potassium supplementation might be especially beneficial as a therapeutic intervention in African-American hypertensives, and suggest a kallikrein mechanism whereby blood pressure might respond to this intervention. 8, [38] [39] [40] These results reinforce the view that the concept of 'race' alone, or some ill-defined biology associated with race, is not necessarily the pivotal or sole determinant of diseases which vary in prevalence by ethnicity (such as hypertension), or of disease-associated traits (such as kallikrein). 41, 42 Indeed, here we found that, although ethnic groups differed in excretion of a putative mediator of blood pressure homeostasis (kallikrein; Table 1), variation in environmental determinants (dietary potassium intake) associated with ethnicity seem to account for a major portion of the effect on kallikrein. Thus, hereditary factors associated with ethnicity need not necessarily be the exclusive determinants of ethnic variations in disease risk.
Finally, since kallikrein is emerging as an attractive 'intermediate phenotype' in the genetic analysis of hypertension, 1, 4 it will be important to account for the multiple determinants of kallikrein in any association or linkage studies of this phenotype, perhaps beginning with analytic adjustment of the trait for the covariates of gender and dietary (or urinary) potassium.
